No Data
US Stock MarketDetailed Quotes
ADAG Adagene
Watchlist
1.260
-0.030-2.33% Close 09/25 16:00 ET
1.2600.0000.00%
Post 16:00 ET
1.310High1.209Low7.10KVolume
1.230Open1.290Pre Close8.68KTurnover0.04%Turnover RatioLossP/E (TTM)55.23MMarket Cap2.10052wk HighLossP/E (Static)43.83MShares0.90052wk Low0.67P/B20.39MFloat Cap31.830Historical High--Dividend TTM16.18MShs Float0.900Historical Low--Div YieldTTM7.84%Amplitude1.223Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Adagene Company
Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.
Revenue Breakdown
Business
Unit:USD
12/31/2022
Stock NameRevenueRatio
Licensing and collaboration revenue9.29M100.00%
News
Adagene Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 09/01/2023 267.65% HC Wainwright & Co. → $5 Reiterates Buy → Buy 04/21/2023 267.65% HC Wainwright & Co. →
Analysts Offer Insights on Healthcare Companies: Oncternal Therapeutics (ONCT), Adagene (ADAG) and Omega Therapeutics (OMGA)
Adagene Reports 1H Results
Comments
2
牛年好兆头！Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--